Barclays lowered the firm’s price target on BioCryst (BCRX) to $9 from $11 and keeps an Equal Weight rating on the shares. The company reported an inline Q3 for Orladeyo with narrowed guidance, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX: